Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics[J]. Kidney Int, 2006, 69(2):213.
[2]
Pozzi A, Voziyan P A, Hudson B G, et al. Regulation of matrix synthesis, remodeling and accumulation in glomerulosclerosis[J]. Curr Pharm Des, 2009, 15(12):1318.
[3]
Eddy A A. Serine proteases, inhibitors and receptors in renal fibrosis[J]. Thromb Haemost, 2009, 101(4):656.
[4]
Catania J M, Chen G, Parrish A R. Role of matrix metalloproteinases in renal pathophysiologies[J]. Am J Physiol Renal Physiol, 2007, 292(3):F905.
[5]
Matsuo S, López-Guisa J M, Cai X, et al. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice[J]. Kidney Int, 2005, 67(6):2221.
[6]
Hu K, Lin L, Tan X, et al. tPA protects renal interstitial fibroblasts and myofibroblasts from apoptosis[J]. J Am Soc Nephrol, 2008, 19(3):503.
[7]
Cai G, Zhang X, Hong Q, et al. Tissue inhibitor of metalloproteinase-1 exacerbated renal interstitial fibrosis through enhancing inflammation[J]. Nephrol Dial Transplant, 2008, 23(6):1861.
Li X, Wang H. Chinese herbal medicine in the treatment of chronic kidney disease[J]. Adv Chronic Kidney Dis, 2005, 12(3):276.
[10]
Wang H, Li J, Yu L, et al. Antifibrotic effect of the Chinese herbs, Astragalusm ongholicus and Angelica sinensis, in a rat model of chronic puromycin aminonucleoside nephrosis[J]. Life Sci, 2004, 74(13):1645.
Meng L, Van Putten V, Qu L, et al. Altered expression of genes profiles modulated by a combination of Astragali Radix and Angelicae Sinensis Radix in obstructed rat kidney[J]. Planta Med, 2010, 76(13):1431.
[13]
Song J, Meng L, Li S, et al. A combination of Chinese herbs, Astragalus membranaceus var. mongholicus and Angelica sinensis, improved renal microvascular insufficiency in 5/6 nephrectomized rats[J]. Vascul Pharmacol, 2009, 50(5/6):185.
[14]
Meng L, Qu L, Tang J, et al. A combination of Chinese herbs, Astragalus membranaceus var. mongholicus and Angelica sinensis, enhanced nitric oxide production in obstructed rat kidney[J]. Vascul Pharmacol, 2007, 47(2/3):174.
[15]
Ishidoya S, Ogata Y, Fukuzaki A, et al. Plasminogen activator inhibitor-1 and tissue-type plasminogen activator are up-regulated during unilateral ureteral obstruction in adult rats[J]. J Urol, 2002, 167(3):1503.
[16]
Ogata Y, Ishidoya S, Fukuzaki A, et al. Upregulated expression of transforming growth factor-beta, type IV collagen, and plasminogen activator inhibitor-1 mRNA are decreased after release of unilateral ureteral obstruction[J]. Tohoku J Exp Med, 2002, 197(3):159.
[17]
Yang J, Shultz R W, Mars W M, et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy [J]. J Clin Invest, 2002, 110(10):1525.
Gonzalez J, Klein J, Chauhan S D, et al. Delayed treatment with plasminogen activator inhibitor-1 decoys reduces tubulointerstitial fibrosis[J]. Exp Biol Med (Maywood), 2009, 234(12):1511.
[21]
Hu K, Wu C, Mars W M, et al. Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling[J]. J Clin Invest, 2007, 117(12):3821.
[22]
Ploplis V A, French E L, Carmeliet P, et al. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice[J]. Blood, 1998, 91(6):2005.
[23]
Munger J S, Harpel J G, Gleizes P E, et al. Latent transforming growth factor-beta: structural features and mechanisms of activation[J]. Kidney Int, 1997, 51(5): 1376.
[24]
Zhang G, Kernan K A, Collins S J, et al. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals[J]. J Am Soc Nephrol, 2007, 18(3):846.
[25]
Wang X, Zhou Y, Tan R, et al. Mice lacking the matrix metalloproteinase-9 gene reduce renal interstitial fibrosis in obstructive nephropathy[J]. Am J Physiol Renal Physiol, 2010, 299(5):F973.
[26]
Aresu L, Benali S, Garbisa S, et al. Matrix metalloproteinases and their role in the renal epithelial mesenchymal transition [J]. Histol Histopathol, 2011, 26(3):307.
[27]
Zheng G, Harris D C. Plasmin in renal interstitial fibrosis: innocent or guilty[J]. Kidney Int, 2004, 66(1):455.
